Merck & Co.
Shares declined $1.32, or 2.8 percent, to $46.69. The third-largest U.S. drugmaker reported a fourth- quarter loss and sales of the Gardasil cervical cancer vaccine that missed analysts' estimates.
Merck & Co.
Shares declined $1.32, or 2.8 percent, to $46.69. The third-largest U.S. drugmaker reported a fourth- quarter loss and sales of the Gardasil cervical cancer vaccine that missed analysts' estimates.
You've reached your monthly free article limit.
Cancel Anytime
Already have digital access? Log in
Print subscriber? Activate digital access